Keyword: FierceBiotech

Fierce 15

FierceBiotech's 2019 Fierce 15

This has been a year for IPOs and buyouts—but private and independent preclinical biotechs are our focus, and we honor them with our Fierce 15 award.
Fierce 15

FierceBiotech's 2019 Fierce 15

This has been the year of the preclinical biotech cash out: So many early-stage, promising young startups have gone public earlier than ever before or sold to an opportunistic pharma. Plenty of private, independent biotechs are still out there, though—and here are 15 you should be watching.